Ocuphire Pharma is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.
Ocuphire Pharma is a publicly traded company on ASE using the ticker symbol RNN.
Detailed information on company financials and operating reports can be found here:
ASE: RNN
Note: Ocuphire Pharma's revenues are gauged from an analysis of company filings.
Investor Activity
Ocuphire Pharma has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
November 20, 2020
18
100%
$21 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Ocuphire Pharma is developing and marketing.
Ocuphire Pharma doesn't have any recent trademark applications, indicating Ocuphire Pharma is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
SUPINOXIN Pharmaceutical products for the prevention and treatment of cancer
07/08/2013
ZORAXEL Pharmaceutical preparations for the treatment of sexual dysfunction
03/15/2011
See all trademarks and details in the Full Report.
Market Share of Ocuphire Pharma's Largest Competitors
A competitive analysis shows these companies are in the same general field as Ocuphire Pharma, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Ocuphire Pharma.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Ocuphire Pharma and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.